Therapix Biosciences (TRPX) - THX-ULD01 to focus on TBI

10:04 EDT 18 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Therapix Biosciences: Therapix reported H117 results and provided a company update in which it announced that the planned development program for sublingual ultra-low dose THC (THX-ULD01) will focus on the treatment of traumatic brain injury (TBI). The program is planned to enter a Phase I pharmacokinetic study in Q417, expected to take one month to complete. The company also reported that the Phase IIa Tourette’s study of THX-TS01 was going smoothly and eight (of 18) patients have completed the trial, seven of whom opted to remain on the drug.
ISIN: US88339A2033

Original Article: Therapix Biosciences (TRPX) - THX-ULD01 to focus on TBI


More From BioPortfolio on "Therapix Biosciences (TRPX) - THX-ULD01 to focus on TBI"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...